{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T06:38:46Z","timestamp":1792996726987,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T00:00:00Z","timestamp":1522454400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s12185-018-2449-8","type":"journal-article","created":{"date-parts":[[2018,3,31]],"date-time":"2018-03-31T04:17:40Z","timestamp":1522469860000},"page":"161-166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical characteristics and outcomes of diffuse large B-cell lymphoma in adolescents and young adults"],"prefix":"10.1007","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-4540","authenticated-orcid":false,"given":"Yasuhiro","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youko","family":"Suehiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Iwasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumasa","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morio","family":"Sawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuo","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroatsu","family":"Iida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,31]]},"reference":[{"key":"2449_CR1","doi-asserted-by":"publisher","first-page":"5803","DOI":"10.1182\/blood-2010-12-283093","volume":"117","author":"WA Wood","year":"2011","unstructured":"Wood WA, Lee SJ. Malignant hematologic diseases in adolescents and young adults. Blood. 2011;117:5803\u201315.","journal-title":"Blood"},{"key":"2449_CR2","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S1470-2045(16)00162-5","volume":"17","author":"A Trama","year":"2016","unstructured":"Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000\u201307: population-based data from EUROCARE-5. Lancet Oncol. 2016;17:896\u2013906.","journal-title":"Lancet Oncol."},{"key":"2449_CR3","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1159\/000360212","volume":"132","author":"O Wolach","year":"2014","unstructured":"Wolach O, Ram R. Adolescents and young adults with non-Hodgkin\u2019s lymphoma: slipping between the cracks. Acta Haematol. 2014;132:279\u201391.","journal-title":"Acta Haematol"},{"key":"2449_CR4","volume-title":"Cancer epidemiology in older adolescents and young adults 15\u201329 years of age, including SEER incidence and survival, 1975\u20132000","author":"WA Bleyer","year":"2006","unstructured":"Bleyer WA, O\u2019Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15\u201329 years of age, including SEER incidence and survival, 1975\u20132000. Bethesda: National Cancer Institute, NIH Pub. No. 06-5767; 2006."},{"key":"2449_CR5","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2141.2008.07393.x","volume":"144","author":"J Hochberg","year":"2009","unstructured":"Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144:24\u201340.","journal-title":"Br J Haematol"},{"key":"2449_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1053\/j.seminoncol.2009.07.009","volume":"36","author":"SM Jaglowski","year":"2009","unstructured":"Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. Semin Oncol. 2009;36:381\u2013418.","journal-title":"Semin Oncol"},{"key":"2449_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1182\/blood-2005-06-2508","volume":"107","author":"LM Morton","year":"2006","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992\u20132001. Blood. 2006;107:265\u201376.","journal-title":"Blood"},{"key":"2449_CR8","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1002\/cncr.25765","volume":"117","author":"PJ Shenoy","year":"2011","unstructured":"Shenoy PJ, Malik N, Nooka A, Sinha R, Ward KC, Brawley OW, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:2530\u201340.","journal-title":"Cancer"},{"key":"2449_CR9","volume-title":"Pathology and genetics of tumours of haematopoietic and lymphoid tissues","author":"ES Jaffe","year":"2001","unstructured":"Jaffe ES, Harris NL, Stein H, Vardiman JW. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001."},{"key":"2449_CR10","doi-asserted-by":"publisher","first-page":"4384","DOI":"10.1182\/blood-2008-07-077982","volume":"112","author":"ES Jaffe","year":"2008","unstructured":"Jaffe ES, Harris NL, Stein H, Isaacson PG. Classification of lymphoid neoplasms: the microscope as a tool for disease discovery. Blood. 2008;112:4384\u201399.","journal-title":"Blood"},{"key":"2449_CR11","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. NCI Sponsored International Working Group. J Clin Oncol. 1999;17:1244.","journal-title":"J Clin Oncol"},{"key":"2449_CR12","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.3109\/10428194.2013.858814","volume":"55","author":"D Coso","year":"2014","unstructured":"Coso D, Garciaz S, Esterni B, Broussais-Guillaumot F, Ivanov V, Aurran-Schleinitz T, et al. Large B-cell lymphomas in adolescents and young adults in comparison to adult patients: a matched-control analysis in 55 patients. Leuk Lymphoma. 2014;55:1849\u201353.","journal-title":"Leuk Lymphoma"},{"key":"2449_CR13","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1182\/blood-2011-10-388470","volume":"119","author":"W Klapper","year":"2012","unstructured":"Klapper W, Kreuz M, Kohler CW, Burkhardt B, Szczepanowski M, Salaverria I, et al. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Blood. 2012;119:1882\u20137.","journal-title":"Blood"},{"key":"2449_CR14","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837\u201342.","journal-title":"Blood"},{"key":"2449_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;329:987\u201394","journal-title":"N Engl J Med."},{"key":"2449_CR16","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","volume":"112","author":"W Stock","year":"2008","unstructured":"Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children\u2019s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646\u201354.","journal-title":"Blood"},{"key":"2449_CR17","doi-asserted-by":"publisher","first-page":"e252","DOI":"10.1038\/bcj.2014.72","volume":"4","author":"F Hayakawa","year":"2014","unstructured":"Hayakawa F, Sakura T, Yujiri T, Kondo E, Fujimaki K, Sasaki O, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol: a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014;4:e252.","journal-title":"Blood Cancer J."},{"key":"2449_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"2449_CR19","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452\u20139.","journal-title":"J Clin Oncol"},{"key":"2449_CR20","doi-asserted-by":"publisher","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","volume":"30","author":"TM Green","year":"2012","unstructured":"Green TM, Young KH, Visco C, Xu-Monette ZY, Orazi A, Go RS, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460\u20137.","journal-title":"J Clin Oncol"},{"key":"2449_CR21","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503\u201311.","journal-title":"Nature"},{"key":"2449_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/bjh.14157","volume":"178","author":"A Johnson","year":"2017","unstructured":"Johnson A, Morosini D, Vergilio JA, Yelensky R, Rosenzweig M, Khaira D, et al. Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets. Br J Haematol. 2017;178:640\u20132.","journal-title":"Br J Haematol."},{"key":"2449_CR23","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1182\/blood-2005-10-4213","volume":"107","author":"I Oschlies","year":"2006","unstructured":"Oschlies I, Klapper W, Zimmermann M, Krams M, Wacker HH, Burkhardt B, et al. Diffuse large B-cell lymphoma in pediatric patients belongs predominantly to the germinal-center type B-cell lymphomas: a clinicopathologic analysis of cases included in the German BFM (Berlin\u2013Frankfurt\u2013Munster) Multicenter Trial. Blood. 2006;107:4047\u201352.","journal-title":"Blood"},{"key":"2449_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/pbc.21619","volume":"51","author":"RR Miles","year":"2008","unstructured":"Miles RR, Raphael M, McCarthy K, Wotherspoon A, Lones MA, Terrier-Lacombe MJ, et al. Pediatric diffuse large B-cell lymphoma demonstrates a high proliferation index, frequent c-Myc protein expression, and a high incidence of germinal center subtype: report of the French\u2013American\u2013British (FAB) International Study Group. Pediatr Blood Cancer. 2008;51:369\u201374.","journal-title":"Pediatr Blood Cancer"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2449-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2449-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,30]],"date-time":"2019-03-30T20:16:33Z","timestamp":1553976993000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2449-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,31]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["2449"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2449-8","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,31]]},"assertion":[{"value":"23 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Hirokazu Nagai\u00a0has received research funding from Janssen Pharmaceutical K. K., Mundipharma K.K., Celgene Corporation, Bayer Yakuhin Ltd., Abbvie G.K., Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Kyowa Hakko Kirin Co., Ltd., and Esai Co., Ltd., and honoraria from Chugai Pharmaceutical Co., Ltd., Mundipharma K.K., Esai Co., Ltd., Sanofi K.K., and Janssen Pharmaceutical K. K. Kazutaka Sunami\u00a0has received research funding from MSD K. K., Celgene Corporation, and honoraria from Celgene Corporation, Ono Pharmaceutical Co., Ltd., Bristol-Myers Squibb. Morio Sawamura has received honoraria from Ono Pharmaceutical Co., Ltd. and Takeda Pharmaceutical Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict-of-interest"}}]}}